First-line CDK 4/6 inhibition shows overall s | EurekAlert!
MONALEESA-2 subgroup analysis of locally assessed PFS. Data cut-off, 2... | Download Scientific Diagram
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
Efficacy of KISQALI® (ribociclib) + AI in 1L Premenopausal | HCP
MONALEESA-2 subgroup analysis of locally assessed PFS. Data cut-off, 2... | Download Scientific Diagram
2021 Update on Systemic Therapy for Breast Cancer | Published in healthbook TIMES Oncology Hematology
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer - ScienceDirect
Making Sense of PALOMA-2 and MONALEESA-2 Data for the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Safety and impact of dose reductions on efficacy in the randomised MONALEESA -2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm - Boyle - 2018 - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
ESMO21: MONALEESA-2 trial demonstrates overall survival benefit - Oncology Central
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
Aleix Prat #PrecisionOncology on Twitter: "📢 #ESMO21 MONALEESA-2 OS final results Overall survival results of postmenopausal patients with HR+/HER2- advanced breast cancer with endocrine therapy + ribociclib Not many drugs show OS
GS2-01: "Overall survival subgroup analysis by metastatic site from the phase3 MONALEESA-2..." - YouTube
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Asco 2019 – Novartis looks to premenopausal survival to reinvigorate Kisqali | Evaluate
Extending overall survival and preserving quality of life in HR+/HER2- advanced breast cancer - touchONCOLOGY
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | NEJM
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer | NEJM
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
Download Poster: Overall Survival with Kisqali® plus Endocrine Therapy in Patients with Advanced Breast Cancer with Visceral Metastases 6
Overall survival (OS) results of the Phase III MONALEESA-3 trial - YouTube
